IP Library Granted Patent US 7,411,000
Granted Patent B2
US 7,411,000 · App. 10/099,408 · Granted Aug 12, 2008

Process of inhibiting cell death in injured cartilage

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,411,000
App. No.
10/099,408
Granted
Aug 12, 2008
Kind
B2
Abstract

Processes for inhibiting apoptotic cell death and glycosaminoglycan release from injured cartilage is provided. Inhibition is accomplished using caspase inhibitors.

Claims (10)

1. A process of inhibiting apoptotic cell death in injured cartilage following traumatic mechanical injury of the cartilage of a human patient, comprising:

a. identifying a human patient having a traumatic mechanical injury to cartilage; and

b. inhibiting the activity of cysteine-aspartate-specific proteases in the injured cartilage within seven days of the injury by administering to the patient a sufficient amount of a fluoromethylketone caspase inhibitor to achieve a concentration of inhibitor in an interstitial fluid which perfuses the injured cartilage of from about 20 μM to about 250 μM, wherein the fluoromethylketone caspase inhibitor is administered by an intra-articular injection.

2. The process of claim 1 wherein the fluoromethylketone caspase inhibitor is benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone.

3. A process of inhibiting glycosaminoglycan release from cartilage following mechanical injury of the cartilage, comprising inhibiting apoptotic cell death in human injured cartilage by contacting the injured cartilage with an effective amount of a fluoromethylketone caspase inhibitor that is a cysteine-aspartate-specific-protease within seven days of traumatic mechanical injury to the cartilage thereby inhibiting glycosaminoglycan release from the cartilage, wherein the fluoromethylketone caspase inhibitor is injected into intra-articular space to achieve a concentration of fluoromethylketone caspase inhibitor in an interstitial fluid which perf uses the injured cartilage of from about 20 μM to about 250 μM.

4. The process of claim 3 wherein the fluoromethylketone caspase inhibitor is benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone.

5. The process of claim 1 or 3 wherein the traumatic mechanical injury of the cartilage is blunt traumatic mechanical injury.

6. The process of claim 1 or 3 wherein the traumatic mechanical injury of the cartilage is external traumatic mechanical injury.

7. The process of claim 1 , wherein the cartilage is articular cartilage.

8. The process of claim 3 , wherein the cartilage is articular cartilage.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 16, 2015
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037302/0559 →
CONFIRMATORY LICENSE Recorded Nov 18, 2008
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021852/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2002
From: D'LIMA, DARRYL; LOTZ, MARTIN; COLWELL, CLIFFORD
To: SCRIPPS RESEARCH INSTITUTE, THE
Reel/Frame 013010/0857 →